Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 7/20 | 0.37 |
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29898842 | 0.98 | KDM4E (0.41) | KDM4EMAPTCYP1A2PARP15PARP10 | |
| SCHEMBL4968774 | 0.94 | CNR1 (0.43) | KDM4EMAPTCYP1A2PARP15PARP10 | |
| SCHEMBL3672284 | 0.90 | CNR1 (0.46) | CNR1CNR2CYP3A4 | |
| SCHEMBL3668330 | 0.82 | MAPT (0.39) | KDM4EMAPTCYP1A2CNR1CNR2 | |
| SCHEMBL6984087 | 0.79 | GPR119 (0.51) | KDM4E | |
| SCHEMBL8535821 | 0.79 | CNR1 (0.43) | KDM4EMAPTCYP1A2CNR1CNR2 | |
| SCHEMBL28001171 | 0.79 | KDM4E (0.50) | KDM4EMAPTCYP1A2MKNK1MKNK2 | |
| SCHEMBL3675628 | 0.79 | POLB (0.46) | KDM4EMAPTALDH1A1L3MBTL1PARP1 | |
| SCHEMBL1503132 | 0.78 | KDM4E (0.49) | KDM4EMAPTCYP1A2MKNK1MKNK2 | |
| SCHEMBL4030545 | 0.78 | KDM4E (0.49) | KDM4EMAPTCYP1A2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300422-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-03-30 | — | — | EP | claimed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | claimed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | claimed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | claimed |
| US-20240190854-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | KING'S COLLEGE LONDON (GB) | 2024-06-13 | — | — | US | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190854-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | HCN2, HCN1, HCN3 | KDM4E 4258/4885MAPT 3427/4885CYP1A2 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.